Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GR
Grace Therapeutics, Inc. Common Stock
GRCE
Mkt Cap
$39.4M
Volume
143.48K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GR
GRCE
GR
Grace Therapeutics, Inc. Common Stock
GRCE
News
·
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
Mkt Cap
$41.0M
Volume
143.47K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
Law firm Holzer & Holzer is investigating whether Grace Therapeutics complied with federal securities laws following the FDA's issuance of a Complete Response Letter for its GTx-104 drug application on April 23, 2026. The CRL cited issues with packaging leachables data, non-clinical toxicology assessments, and manufacturing deficiencies, causing the company's stock price to decline. The firm is seeking investors who suffered losses to join potential litigation.
GlobeNewswire Inc. · Jun 3, 2026
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
Grace Therapeutics announced that its STRIVE-ON Phase 3 trial results for GTx-104, an injectable nimodipine formulation for aneurysmal subarachnoid hemorrhage (aSAH), have been accepted for presentation at the 2026 American Academy of Neurology annual meeting. The trial met its primary endpoint, showing GTx-104 reduced clinically significant hypotension by 19% compared to oral nimodipine (28% vs 35%), with 54% of patients achieving 95%+ relative dose intensity versus only 8% on oral nimodipine. Additional benefits included fewer ICU readmissions and better functional outcomes at 90 days.
GlobeNewswire Inc. · Apr 14, 2026
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Grace Therapeutics announced that CEO Prashant Kohli will present at TD Cowen's 46th Annual Health Care Conference on March 4, 2026. The company also revealed that the FDA established April 23, 2026 as the PDUFA target date for review of GTx-104, an IV infusion formulation of nimodipine being developed for aneurysmal subarachnoid hemorrhage (aSAH) treatment.
GlobeNewswire Inc. · Feb 25, 2026
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Grace Therapeutics announced that its Phase 3 STRIVE-ON trial for GTx-104, a novel injectable formulation of nimodipine, met its primary endpoint and showed evidence of clinical benefit over oral nimodipine in aSAH patients. The company plans to submit a New Drug Application (NDA) for GTx-104 in the first half of 2025.
GlobeNewswire Inc. · Feb 10, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
GR
GRCE
Grace Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
GRCE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any GRCE yet.
Related Tickers
Earnings